The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
The cannabinoid system and microglia in health and disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the central nervous system (CNS), CB2 is minimally expressed under basal conditions, but its expression is upregulated in microglia, the resident immune cells of the brain, during neuroinflammation (Duffy et al., 2021).”
From Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters (2025) · cites this paper as Duffy et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547
Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N. B., First, M. B., et al. (2019) · Pain · doi:10.1097/j.pain.0000000000001384 · Cited by 3,478
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979
A Lineage of Myeloid Cells Independent of Myb and Hematopoietic Stem Cells
Schulz, C., Perdiguero, E. G., Chorro, L., Szabo-Rogers, H., Cagnard, N., Kierdorf, K., Prinz, M., Wu, B., Jacobsen, S. E. W., Pollard, J. W., et al. (2012) · Science · doi:10.1126/science.1219179 · Cited by 2,578
Identification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543
Research works printed but not linked: 195
- Alberti, 2017, (-)-β-Caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis, Int. J. Mol. Sci., 18, 10.3390/ijms18040691 · DOI
- Anavi-Goffer, 2012, Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids, J. Biol. Chem., 287, 91, 10.1074/jbc.M111.296020 · DOI
- Araujo, 2019, The endocannabinoid system as a window into microglial biology and its relationship to autism, Front. Cell. Neurosci., 13, 424, 10.3389/fncel.2019.00424 · DOI
- Arévalo-Martín, 2003, Therapeutic action of cannabinoids in a murine model of multiple sclerosis, J. Neurosci., 23, 2511, 10.1523/JNEUROSCI.23-07-02511.2003 · DOI · Paper page
- Askari, 2019, Combination of Imipramine, a sphingomyelinase inhibitor, and β-caryophyllene improve their therapeutic effects on experimental autoimmune encephalomyelitis (EAE), Int. Immunopharm., 77, 105923, 10.1016/j.intimp.2019.105923 · DOI
- Aso, 2016, Cannabinoid receptor 2 participates in amyloid-β processing in a mouse model of alzheimer's disease but plays a minor role in the therapeutic properties of a cannabis-based medicine, J Alzheimers Dis, 51, 489, 10.3233/JAD-150913 · DOI
- Bauer, 2019, Inflammation in psychiatric disorders: what comes first?, Ann. N. Y. Acad. Sci., 1437, 57, 10.1111/nyas.13712 · DOI · Paper page
- Baxter, 2007, The origin and application of experimental autoimmune encephalomyelitis, Nat. Rev. Immunol., 7, 904, 10.1038/nri2190 · DOI · Paper page
- Benito, 2003, Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains, J. Neurosci., 23, 11136, 10.1523/JNEUROSCI.23-35-11136.2003 · DOI · Paper page
- Bernstein, 2009, Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy, Expert Rev. Neurother., 9, 1059, 10.1586/ern.09.59 · DOI · Paper page
- Bie, 2018, An overview of the cannabinoid type 2 receptor system and its therapeutic potential, Curr. Opin. Anaesthesiol., 31, 407, 10.1097/ACO.0000000000000616 · DOI · Paper page
- Bilsland, 2006, Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice, Faseb. J., 20, 1003, 10.1096/fj.05-4743fje · DOI · Paper page
- Bilsland, 2008, The endocannabinoid system in amyotrophic lateral sclerosis, Curr. Pharmaceut. Des., 14, 2306, 10.2174/138161208785740081 · DOI
- Borowska-Fielding, 2018, Revisiting cannabinoid receptor 2 expression and function in murine retina, Neuropharmacology, 141, 21, 10.1016/j.neuropharm.2018.08.007 · doi:10.1016/j.neuropharm.2018.08.007
- Burgos, 2012, Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells, Eur. J. Pharmacol., 682, 62, 10.1016/j.ejphar.2012.02.008 · DOI
- Cabral, 2005, Cannabinoid receptors in microglia of the central nervous system: immune functional relevance, J. Leukoc. Biol., 78, 1192, 10.1189/jlb.0405216 · DOI · Paper page
- Carrier, 2004, Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism, Mol. Pharmacol., 65, 999, 10.1124/mol.65.4.999 · DOI · Paper page
- Carrillo-Salinas, 2014, A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis, PloS One, 9, 10.1371/journal.pone.0094733 · DOI
- Cass, 2014, CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex, Mol. Psychiatr., 19, 536, 10.1038/mp.2014.14 · DOI · Paper page
- Chen, 2018, Microglia in pain: detrimental and protective roles in pathogenesis and resolution of pain, Neuron, 100, 1292, 10.1016/j.neuron.2018.11.009 · DOI · Paper page
- Chiu, 2013, A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model, Cell Rep., 4, 385, 10.1016/j.celrep.2013.06.018 · DOI · Paper page
- Chung, 2011, Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation, J. Immunol., 187, 6508, 10.4049/jimmunol.1102435 · DOI
- Chung, 2016, CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease, Exp. Mol. Med., 48, 10.1038/emm.2015.100 · DOI · Paper page
- Concannon, 2015, Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease, Exp. Neurol., 269, 133, 10.1016/j.expneurol.2015.04.007 · DOI
- Concannon, 2016, Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease, Exp. Neurol., 283, 204, 10.1016/j.expneurol.2016.06.014 · DOI
- Contestabile, 2011, The history of the cholinergic hypothesis, Behav. Brain Res., 221, 334, 10.1016/j.bbr.2009.12.044 · DOI · Paper page
- Correa, 2011, The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells, Brain Behav. Immun., 25, 736, 10.1016/j.bbi.2011.01.020 · DOI
- Corsi-Zuelli, 2017, Neuroimmune interactions in schizophrenia: focus on vagus nerve stimulation and activation of the alpha-7 nicotinic acetylcholine receptor, Front. Immunol., 8, 618, 10.3389/fimmu.2017.00618 · DOI
- de Lago, 2012, Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects, Neuropharmacology, 62, 2299, 10.1016/j.neuropharm.2012.01.030 · DOI
- Deleidi, 2010, The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration, J. Neurosci., 30, 16091, 10.1523/JNEUROSCI.2400-10.2010 · DOI
- DeMarco, 2008, Chapter 1 - anatomy, physiology, and effects of pain, 3
- Di Giorgio, 2008, Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation, Cell Stem Cell, 3, 637, 10.1016/j.stem.2008.09.017 · DOI · Paper page
- Di Marzo, 2015, Endocannabinoid signalling and the deteriorating brain, Nat. Rev. Neurosci., 16, 30, 10.1038/nrn3876 · DOI · Paper page
- Dickson, 2012, Parkinson's disease and parkinsonism: neuropathology, Cold Spring Harb Perspect Med, 2, 10.1101/cshperspect.a009258 · DOI · Paper page
- Duffy, 2014, The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis, Mult Scler Int, 2014, 285245
- Duncan, 2014, Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms, Mov. Disord., 29, 195, 10.1002/mds.25664 · DOI · Paper page
- Ehrhart, 2005, Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation, J. Neuroinflammation, 2, 29, 10.1186/1742-2094-2-29 · DOI · Paper page
- El-Alfy, 2010, Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L, Pharmacol. Biochem. Behav., 95, 434, 10.1016/j.pbb.2010.03.004 · DOI · Paper page
- ElBatsh, 2012, Anxiogenic-like effects of chronic cannabidiol administration in rats, Psychopharmacology (Berlin), 221, 239, 10.1007/s00213-011-2566-z · DOI
- Espejo-Porras, 2019, Targeting glial cannabinoid CB, Br. J. Pharmacol., 176, 1585
- Espejo-Porras, 2015, Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders, J. Neuroimmune Pharmacol., 10, 233, 10.1007/s11481-015-9602-4 · DOI
- Esposito, 2007, Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence, J. Pharmacol. Exp. Therapeut., 322, 1144, 10.1124/jpet.107.121566 · DOI
- Fakhfouri, 2012, WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway, Neuropharmacology, 63, 653, 10.1016/j.neuropharm.2012.05.013 · DOI
- Fernández-Suárez, 2014, Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model, Neurobiol. Aging, 35, 2603, 10.1016/j.neurobiolaging.2014.05.021 · DOI
- Foran, 2009, Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis, Antioxidants Redox Signal., 11, 1587, 10.1089/ars.2009.2444 · DOI · Paper page
- Franco, 2019, Potentiation of cannabinoid signaling in microglia by adenosine A2A receptor antagonists, Glia, 67, 2410, 10.1002/glia.23694 · DOI
- Franco, 2019, Potentiation of cannabinoid signaling in microglia by adenosine A, Glia, 67, 2410, 10.1002/glia.23694 · DOI
- Franklin, 2003, Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors, Eur. J. Pharmacol., 474, 195, 10.1016/S0014-2999(03)02074-0 · DOI
- Frost, 2016, Microglia: architects of the developing nervous system, Trends Cell Biol., 26, 587, 10.1016/j.tcb.2016.02.006 · DOI · Paper page
- Gao, 2008, Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration, J. Neurosci., 28, 7687, 10.1523/JNEUROSCI.0143-07.2008 · DOI · Paper page
- García, 2011, Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease, Br. J. Pharmacol., 163, 1495, 10.1111/j.1476-5381.2011.01278.x · DOI · Paper page
- García-Gutiérrez, 2011, Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice, J. Psychopharmacol., 25, 111, 10.1177/0269881110379507 · DOI · Paper page
- García-Gutiérrez, 2018, Alterations in gene and protein expression of cannabinoid CB(2) and GPR55 receptors in the dorsolateral prefrontal cortex of suicide victims, Neurotherapeutics, 15, 796, 10.1007/s13311-018-0610-y · DOI
- Ginhoux, 2010, Fate mapping analysis reveals that adult microglia derive from primitive macrophages, Science, 330, 841, 10.1126/science.1194637 · DOI · Paper page
- Goldenberg, 2012, Multiple sclerosis review, P T, 37, 175
- Gomes, 2014, Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia, Int. J. Neuropsychopharmacol., 18, 10.1093/ijnp/pyu018 · DOI · Paper page
- Granja, 2012, A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis, J. Neuroimmune Pharmacol., 7, 1002, 10.1007/s11481-012-9399-3 · DOI · Paper page
- Gómez-Gálvez, 2016, Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 64, 200, 10.1016/j.pnpbp.2015.03.017 · DOI · Paper page
- Habib, 2011, Emerging drugs for amyotrophic lateral sclerosis, Expet Opin. Emerg. Drugs, 16, 537, 10.1517/14728214.2011.604312 · DOI
- Haight, 2019, Microglial modulation as a target for chronic pain: from the bench to the bedside and back, Anesth. Analg., 128, 737, 10.1213/ANE.0000000000004033 · DOI
- Hardiman, 2011, Clinical diagnosis and management of amyotrophic lateral sclerosis, Nat. Rev. Neurol., 7, 639, 10.1038/nrneurol.2011.153 · DOI · Paper page
- Henstridge, 2010, GPR55 ligands promote receptor coupling to multiple signalling pathways, Br. J. Pharmacol., 160, 604, 10.1111/j.1476-5381.2009.00625.x · DOI · Paper page
- Hickman, 2013, The microglial sensome revealed by direct RNA sequencing, Nat. Neurosci., 16, 1896, 10.1038/nn.3554 · DOI · Paper page
- Hill, 2009, The endocannabinoid system and the treatment of mood and anxiety disorders, CNS Neurol. Disord. - Drug Targets, 8, 451, 10.2174/187152709789824624 · DOI
- Horti, 2010, Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2), Bioorg. Med. Chem., 18, 5202, 10.1016/j.bmc.2010.05.058 · DOI
- Howlett, 1986, Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs, Mol. Pharmacol., 29, 307, 10.1016/S0026-895X(25)10219-8 · DOI · Paper page
- Hu, 2015, Microglial and macrophage polarization-new prospects for brain repair, Nat. Rev. Neurol., 11, 56, 10.1038/nrneurol.2014.207 · DOI · Paper page
- Javed, 2016, Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson's disease, Front. Neurosci., 10, 321, 10.3389/fnins.2016.00321 · DOI · Paper page
- Jeong, 2016, High-resolution transcriptome analysis reveals neuropathic pain gene-expression signatures in spinal microglia after nerve injury, Pain, 157, 964, 10.1097/j.pain.0000000000000470 · DOI
- Ji, 2013, Glia and pain: is chronic pain a gliopathy?, Pain, 154, S10, 10.1016/j.pain.2013.06.022 · DOI · Paper page
- Jin, 2003, p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain, J. Neurosci., 23, 4017, 10.1523/JNEUROSCI.23-10-04017.2003 · DOI · Paper page
- Johnston, 2006, Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London, J. Neurol., 253, 1642, 10.1007/s00415-006-0195-y · DOI · Paper page
- Kalia, 2015, Parkinson's disease, Lancet, 386, 896, 10.1016/S0140-6736(14)61393-3 · DOI · Paper page
- Kato, 2016, Pattern recognition receptors in chronic pain: mechanisms and therapeutic implications, Eur. J. Pharmacol., 788, 261, 10.1016/j.ejphar.2016.06.039 · DOI
- Kim, 2006, AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis, Eur. J. Pharmacol., 542, 100, 10.1016/j.ejphar.2006.05.025 · DOI
- Kong, 2014, Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS, Cell. Immunol., 287, 1, 10.1016/j.cellimm.2013.11.002 · DOI
- Koppel, 2014, CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease, Mol. Med., 20, 29, 10.2119/molmed.2013.00140.revised · DOI
- Kozela, 2011, Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice, Br. J. Pharmacol., 163, 1507, 10.1111/j.1476-5381.2011.01379.x · DOI · Paper page
- Kreutzberg, 1996, Microglia: a sensor for pathological events in the CNS, Trends Neurosci., 19, 312, 10.1016/0166-2236(96)10049-7 · DOI · Paper page
- Lafenêtre, 2007, The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction, Pharmacol. Res., 56, 367, 10.1016/j.phrs.2007.09.006 · DOI
- Lauckner, 2008, GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current, Proc. Natl. Acad. Sci. U. S. A., 105, 2699, 10.1073/pnas.0711278105 · DOI · Paper page
- Le, 2016, Protective microglia and their regulation in Parkinson's disease, Front. Mol. Neurosci., 9, 89, 10.3389/fnmol.2016.00089 · DOI
- Lee, 2010, Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1, J. Immunol., 185, 615, 10.4049/jimmunol.0903480 · DOI · Paper page
- Li, 2019, CB2 cannabinoid receptor agonist ameliorates novel object recognition but not spatial memory in transgenic APP/PS1 mice, Neurosci. Lett., 707, 134286, 10.1016/j.neulet.2019.134286 · DOI
- Lisboa, 2016, Microglial cells as a link between cannabinoids and the immune hypothesis of psychiatric disorders, Front. Neurol., 7, 5, 10.3389/fneur.2016.00005 · DOI
- Lisboa, 2018, Repeated social defeat-induced neuroinflammation, anxiety-like behavior and resistance to fear extinction were attenuated by the cannabinoid receptor agonist WIN55,212-2, Neuropsychopharmacology, 43, 1924, 10.1038/s41386-018-0064-2 · DOI
- Liu, 2017, TNF-α differentially regulates synaptic plasticity in the Hippocampus and spinal cord by microglia-dependent mechanisms after peripheral nerve injury, J. Neurosci., 37, 871, 10.1523/JNEUROSCI.2235-16.2016 · DOI · Paper page
- Lopez-Rodriguez, 2014, Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats, Br. J. Pharmacol., 171, 1435, 10.1111/bph.12519 · DOI
- Lou, 2018, The inhibition of CB, J. Neuroimmunol., 317, 37, 10.1016/j.jneuroim.2018.02.001 · DOI
- Lourbopoulos, 2011, Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis, Brain Res., 1390, 126, 10.1016/j.brainres.2011.03.020 · DOI
- Luongo, 2013, Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice, CNS Neurol. Disord. - Drug Targets, 12, 45, 10.2174/1871527311312010009 · doi:10.2174/1871527311312010009
- Luongo, 2010, 1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice, Neurobiol. Dis., 37, 177, 10.1016/j.nbd.2009.09.021 · DOI
- López, 2018, Cannabinoid CB, J. Neuroinflammation, 15, 158, 10.1186/s12974-018-1174-9 · DOI · Paper page
- Lü, 2004, [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia], Di Yi Jun Yi Da Xue Xue Bao, 24, 1251
- Ma, 2015, Activation of murine microglial N9 cells is attenuated through cannabinoid receptor CB2 signaling, Biochem. Biophys. Res. Commun., 458, 92, 10.1016/j.bbrc.2015.01.073 · DOI
- Mackie, 1992, Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells, Proc. Natl. Acad. Sci. U. S. A., 89, 3825, 10.1073/pnas.89.9.3825 · DOI · Paper page
- Malek, 2015, Anandamide, acting via CB2 receptors, alleviates LPS-induced neuroinflammation in rat primary microglial cultures, Neural Plast., 130639
- Mangieri, 2007, Enhancement of endocannabinoid signaling and the pharmacotherapy of depression, Pharmacol. Res., 56, 360, 10.1016/j.phrs.2007.09.003 · DOI
- Manterola, 2018, Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination, Biochem. Pharmacol., 157, 189, 10.1016/j.bcp.2018.07.042 · DOI
- Martín-Moreno, 2011, Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease, Mol. Pharmacol., 79, 964, 10.1124/mol.111.071290 · DOI · Paper page
- Masters, 2012, Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease, Cold Spring Harb Perspect Med, 2, a006262, 10.1101/cshperspect.a006262 · DOI · Paper page
- McCabe, 2017, Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson's disease, J. Neuroimmunol., 310, 103, 10.1016/j.jneuroim.2017.07.007 · DOI
- Mecha, 2016, Microglia activation states and cannabinoid system: therapeutic implications, Pharmacol. Ther., 166, 40, 10.1016/j.pharmthera.2016.06.011 · DOI · Paper page
- Mecha, 2015, Endocannabinoids drive the acquisition of an alternative phenotype in microglia, Brain Behav. Immun., 49, 233, 10.1016/j.bbi.2015.06.002 · DOI · Paper page
- Mecha, 2013, Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors, Neurobiol. Dis., 59, 141, 10.1016/j.nbd.2013.06.016 · DOI · Paper page
- Mecha, 2018, 2-AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs, Glia, 66, 1447, 10.1002/glia.23317 · DOI
- Mestre, 2005, Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis, J. Neurochem., 92, 1327, 10.1111/j.1471-4159.2004.02979.x · DOI
- Miyaoka, 2007, Possible antipsychotic effects of minocycline in patients with schizophrenia, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 31, 304, 10.1016/j.pnpbp.2006.08.013 · DOI
- Miüller, 2007, The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view, J. Neural. Transm., Suppl, 269
- Montanari, 2019, Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment, Eur. J. Med. Chem., 178, 243, 10.1016/j.ejmech.2019.05.080 · DOI
- Moreira, 2009, Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression, Best Pract. Res. Clin. Endocrinol. Metabol., 23, 133, 10.1016/j.beem.2008.09.003 · DOI · Paper page
- Moreno-García, 2020, Gene expression analysis of astrocyte and microglia endocannabinoid signaling during autoimmune demyelination, Biomolecules, 10, 10.3390/biom10091228 · DOI
- Murphy, 2012, The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation, J. Neuroinflammation, 9, 79, 10.1186/1742-2094-9-79 · DOI
- Müller-Vahl, 2008, Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia, Expert Rev. Neurother., 8, 1037, 10.1586/14737175.8.7.1037 · DOI
- Navarrete, 2018, Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy, J. Neuroinflammation, 15, 64, 10.1186/s12974-018-1103-y · DOI
- Navarrete, 2020, Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis, Neurobiol. Dis., 143, 104994, 10.1016/j.nbd.2020.104994 · DOI
- Navarro, 2018, Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia, Brain Behav. Immun., 67, 139, 10.1016/j.bbi.2017.08.015 · DOI
- Navarro, 2018, Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB, Brain Behav. Immun., 67, 139, 10.1016/j.bbi.2017.08.015 · DOI
- Nent, 2019, CB2 receptor deletion on myeloid cells enhanced mechanical allodynia in a mouse model of neuropathic pain, Sci. Rep., 9, 7468, 10.1038/s41598-019-43858-4 · DOI
- Nimmerjahn, 2005, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, Science, 308, 1314, 10.1126/science.1110647 · DOI · Paper page
- Niu, 2017, Activation of dorsal horn cannabinoid CB2 receptor suppresses the expression of P2Y, J. Neuroinflammation, 14, 185, 10.1186/s12974-017-0960-0 · DOI
- Noyce, 2012, Meta-analysis of early nonmotor features and risk factors for Parkinson disease, Ann. Neurol., 72, 893, 10.1002/ana.23687 · DOI · Paper page
- Ojha, 2016, β-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease, Mol. Cell. Biochem., 418, 59, 10.1007/s11010-016-2733-y · DOI · Paper page
- Oka, 2007, Identification of GPR55 as a lysophosphatidylinositol receptor, Biochem. Biophys. Res. Commun., 362, 928, 10.1016/j.bbrc.2007.08.078 · DOI · Paper page
- Ortega-Alvaro, 2011, Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice, Neuropsychopharmacology, 36, 1489, 10.1038/npp.2011.34 · DOI · Paper page
- Ortega-Gutiérrez, 2005, Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis, Faseb. J., 19, 1338, 10.1096/fj.04-2464fje · DOI
- Ouali Alami, 2018, NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS, EMBO J., 37, 10.15252/embj.201798697 · DOI
- Passavanti, 2019, Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review, Syst. Rev., 8, 9, 10.1186/s13643-018-0934-z · DOI
- Paszcuk, 2011, Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases, PloS One, 6, 10.1371/journal.pone.0024034 · DOI
- Perry, 1994, Modulation of microglia phenotype, Neuropathol. Appl. Neurobiol., 20, 177
- Price, 2009, WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease, Eur. J. Neurosci., 29, 2177, 10.1111/j.1460-9568.2009.06764.x · DOI · Paper page
- Puffenbarger, 2000, Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells, Glia, 29, 58, 10.1002/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.0.CO;2-W · DOI · Paper page
- Racz, 2008, Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain, J. Neurosci., 28, 12125, 10.1523/JNEUROSCI.3400-08.2008 · DOI · Paper page
- Raghavendra, 2003, Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy, J. Pharmacol. Exp. Therapeut., 306, 624, 10.1124/jpet.103.052407 · DOI · Paper page
- Rahimi, 2015, Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice, Neuroscience, 290, 279, 10.1016/j.neuroscience.2015.01.030 · DOI
- Rahn, 2014, Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery, Mol. Pain, 10, 27, 10.1186/1744-8069-10-27 · DOI
- Raman, 2004, Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid, Amyotroph Lateral Scler., 5, 33
- Ramírez, 2005, Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation, J. Neurosci., 25, 1904, 10.1523/JNEUROSCI.4540-04.2005 · DOI · Paper page
- Renton, 2014, State of play in amyotrophic lateral sclerosis genetics, Nat. Neurosci., 17, 17, 10.1038/nn.3584 · DOI · Paper page
- Reyes-Resina, 2018, Molecular and functional interaction between GPR18 and cannabinoid CB2 G-protein-coupled receptors. Relevance in neurodegenerative diseases, Biochem. Pharmacol., 157, 169, 10.1016/j.bcp.2018.06.001 · DOI
- Reynolds, 2008, Nitrated alpha-synuclein and microglial neuroregulatory activities, J. Neuroimmune Pharmacol., 3, 59, 10.1007/s11481-008-9100-z · DOI
- Ribeiro, 2013, Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis, Neuroscience, 254, 427, 10.1016/j.neuroscience.2013.09.005 · DOI
- Roche, 2010, Brain CB₂ receptors: implications for neuropsychiatric disorders, Pharmaceuticals, 3, 2517, 10.3390/ph3082517 · DOI
- Rodríguez-Cueto, 2014, Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias, Br. J. Pharmacol., 171, 1472, 10.1111/bph.12283 · DOI
- Rolak, 2003, Multiple sclerosis: it's not the disease you thought it was, Clin. Med. Res., 1, 57, 10.3121/cmr.1.1.57 · DOI
- Rothstein, 2017, Edaravone: a new drug approved for ALS, Cell, 171, 725, 10.1016/j.cell.2017.10.011 · DOI · Paper page
- Río-Hortega, 1919, El tercer elemento de los centros nerviosos I. La microglía en estado normal, Boletín de la Sociedad Española de Biología, 9, 68
- Savonenko, 2015, Cannabinoid CB2 receptors in a mouse model of Aβ amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation, PloS One, 10, 10.1371/journal.pone.0129618 · DOI
- Sawada, 2014, Suppression of bone marrow-derived microglia in the amygdala improves anxiety-like behavior induced by chronic partial sciatic nerve ligation in mice, Pain, 155, 1762, 10.1016/j.pain.2014.05.031 · DOI
- Schmöle, 2015, Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model, Neurobiol. Aging, 36, 710, 10.1016/j.neurobiolaging.2014.09.019 · DOI
- Schmöle, 2018, Cannabinoid receptor 2-deficiency ameliorates disease symptoms in a mouse model with alzheimer's disease-like pathology, J Alzheimers Dis, 64, 379, 10.3233/JAD-180230 · DOI
- Scholz, 2019, The IASP classification of chronic pain for ICD-11: chronic neuropathic pain, Pain, 160, 53, 10.1097/j.pain.0000000000001365 · DOI · Paper page
- Sherer, 2003, Selective microglial activation in the rat rotenone model of Parkinson's disease, Neurosci. Lett., 341, 87, 10.1016/S0304-3940(03)00172-1 · DOI · Paper page
- Shiue, 2017, Continuous intrathecal infusion of cannabinoid receptor agonists attenuates nerve ligation-induced pain in rats, Reg. Anesth. Pain Med., 42, 499, 10.1097/AAP.0000000000000601 · DOI
- Shoemaker, 2007, The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset, J. Neurochem., 101, 87, 10.1111/j.1471-4159.2006.04346.x · DOI · Paper page
- Smeyne, 2016, Assessment of the effects of MPTP and paraquat on dopaminergic neurons and microglia in the substantia nigra pars compacta of C57BL/6 mice, PloS One, 11, 10.1371/journal.pone.0164094 · DOI
- Solas, 2013, CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients, Neurobiol. Aging, 34, 805, 10.1016/j.neurobiolaging.2012.06.005 · DOI · Paper page
- Spillantini, 1997, Alpha-synuclein in lewy bodies, Nature, 388, 839, 10.1038/42166 · DOI · Paper page
- Stella, 2010, Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas, Glia, 58, 1017, 10.1002/glia.20983 · DOI · Paper page
- Stoll, 1999, The role of microglia and macrophages in the pathophysiology of the CNS, Prog. Neurobiol., 58, 233, 10.1016/S0301-0082(98)00083-5 · DOI · Paper page
- Sun, 2007, New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis, Pain, 129, 64
- Suárez-Pinilla, 2014, Immune system: a possible nexus between cannabinoids and psychosis, Brain Behav. Immun., 40, 269, 10.1016/j.bbi.2014.01.018 · DOI
- Talarico, 2019, Modulation of the cannabinoid system: a new perspective for the treatment of the alzheimer's disease, Curr. Neuropharmacol., 17, 176, 10.2174/1570159X16666180702144644 · DOI
- Taylor, 2015, Microglia disrupt mesolimbic reward circuitry in chronic pain, J. Neurosci., 35, 8442, 10.1523/JNEUROSCI.4036-14.2015 · DOI · Paper page
- Ternianov, 2012, Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine, Neurobiol. Aging, 33, 421, 10.1016/j.neurobiolaging.2010.09.012 · DOI
- Tolon, 2009, The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages, Brain Res., 1283, 148, 10.1016/j.brainres.2009.05.098 · DOI
- Toth, 2010, Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain, Mol. Pain, 6, 16, 10.1186/1744-8069-6-16 · DOI
- Traxinger, 2013, Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997-2011, Neurol Clin Pract, 3, 313, 10.1212/CPJ.0b013e3182a1b8ab · DOI
- Tsuda, 2005, Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia, Trends Neurosci., 28, 101, 10.1016/j.tins.2004.12.002 · DOI · Paper page
- Tsuda, 2003, P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury, Nature, 424, 778, 10.1038/nature01786 · DOI · Paper page
- Viscomi, 2009, Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway, J. Neurosci., 29, 4564, 10.1523/JNEUROSCI.0786-09.2009 · DOI · Paper page
- Walsh, 2011, Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat, Neuroscience, 175, 251, 10.1016/j.neuroscience.2010.12.005 · DOI
- Walter, 2003, Nonpsychotropic cannabinoid receptors regulate microglial cell migration, J. Neurosci., 23, 1398, 10.1523/JNEUROSCI.23-04-01398.2003 · DOI · Paper page
- Wang, 2020, Spinal cannabinoid receptor 2 activation reduces hypersensitivity associated with bone cancer pain and improves the integrity of the blood-spinal cord barrier, Reg. Anesth. Pain Med., 45, 783, 10.1136/rapm-2019-101262 · DOI
- Wen, 2018, WWL70 protects against chronic constriction injury-induced neuropathic pain in mice by cannabinoid receptor-independent mechanisms, J. Neuroinflammation, 15, 9, 10.1186/s12974-017-1045-9 · DOI
- Wen, 2015, Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis, Neuropharmacology, 99, 196, 10.1016/j.neuropharm.2015.07.010 · DOI
- Weydt, 2005, Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis, Neuroreport, 16, 527, 10.1097/00001756-200504250-00001 · DOI
- Whyte, 2009, The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo, Proc. Natl. Acad. Sci. U. S. A., 106, 16511, 10.1073/pnas.0902743106 · DOI · Paper page
- Witting, 2006, Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection, Proc. Natl. Acad. Sci. U. S. A., 103, 6362, 10.1073/pnas.0510418103 · DOI
- Woolf, 2010, What is this thing called pain?, J. Clin. Invest., 120, 3742, 10.1172/JCI45178 · DOI · Paper page
- Wu, 2013, Activation of the CB2 receptor system reverses amyloid-induced memory deficiency, Neurobiol. Aging, 34, 791, 10.1016/j.neurobiolaging.2012.06.011 · DOI · Paper page
- Wu, 2019, Cannabinoid type 2 receptor system modulates paclitaxel-induced microglial dysregulation and central sensitization in rats, J. Pain, 20, 501, 10.1016/j.jpain.2018.10.007 · DOI
- Wu, 2017, Activation of CB, Eur. J. Pharmacol., 811, 12, 10.1016/j.ejphar.2017.05.044 · DOI
- Xu, 2016, Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic post-ischemic pain model of complex regional pain syndrome type I in rats, Eur. J. Neurosci., 44, 3046, 10.1111/ejn.13414 · DOI
- Yang, 2019, Activation of spinal macrophage-inducible C-type lectin induces mechanical allodynia and microglial activation in rats, Neurosci. Lett., 690, 42, 10.1016/j.neulet.2018.10.017 · DOI
- Yaqub, 2015, Pain in the USA: states of suffering, Lancet, 386, 839, 10.1016/S0140-6736(15)00041-0 · DOI
- Yiangou, 2006, COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord, BMC Neurol., 6, 12, 10.1186/1471-2377-6-12 · DOI · Paper page
- Yum, 2009, Clinical perspectives on autoimmune processes in schizophrenia, Psychiatr. Clin., 32, 795
- Zamberletti, 2015, Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats, Eur. Neuropsychopharmacol, 25, 2404, 10.1016/j.euroneuro.2015.09.021 · DOI
- Zanelati, 2010, Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors, Br. J. Pharmacol., 159, 122, 10.1111/j.1476-5381.2009.00521.x · DOI · Paper page
- Zhang, 2011, Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis, Brain Pathol., 21, 544, 10.1111/j.1750-3639.2011.00477.x · DOI
- Zhang, 2007, Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model, J. Cerebr. Blood Flow Metabol., 27, 1387, 10.1038/sj.jcbfm.9600447 · DOI · Paper page
- Zhang, 2007, Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein, Glia, 55, 1178, 10.1002/glia.20532 · DOI · Paper page
- Zhou, 2017, Microglia polarization with M1/M2 phenotype changes in rd1 mouse model of retinal degeneration, Front. Neuroanat., 11, 77, 10.3389/fnana.2017.00077 · DOI · Paper page
- Zoccolella, 2009, Current and emerging treatments for amyotrophic lateral sclerosis, Neuropsychiatric Dis. Treat., 5, 577, 10.2147/NDT.S7788 · DOI
Cited by
Cannabinoids in Chronic Pain: Therapeutic Potential Through Microglia Modulation
van den Hoogen, N. J., Harding, E. K., Davidson, C. E. D., & Trang, T. (2022) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.816747 · Cited by 45
Lee, H.-L., Jung, K.-M., Fotio, Y., Squire, E., Palese, F., Lin, L., Torrens, A., Ahmed, F., Mabou Tagne, A., Ramirez, J., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.04.017 · Cited by 38
Guadalupi, L., Mandolesi, G., Vanni, V., Balletta, S., Caioli, S., Pavlovic, A., De Vito, F., Fresegna, D., Sanna, K., Vitiello, L., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109940 · Cited by 22
“Evidence suggests cannabinoids as critical players in promoting a reparative state of microglia in EAE, however the precise mechanisms underlying this effect need to be further defined (Tanaka et al., 2020; Duffy et al., 2021).”
Laloli, K. J., Rentsch, P., Stayte, S., & Vissel, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1682979 · Cited by 3
Metadata
- Authors
- Duffy, S. S., Hayes, J. P., Fiore, N. T., & Moalem-Taylor, G.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 190
- Pages
- 108555
- ISSN
- 0028-3908
- Cited by
- 94
- References
- 65
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- National Health and Medical Research Council (APP1162060)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The cannabinoid system and microglia in health and disease. https://app.cochat.ai/papers/10.1016/j.neuropharm.2021.108555
- The paper
- Duffy, S. S., Hayes, J. P., Fiore, N. T., & Moalem-Taylor, G. (2021). The cannabinoid system and microglia in health and disease. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2021.108555
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.